GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » 3-Year RORE %

Nexalin Technology (Nexalin Technology) 3-Year RORE % : -17.04% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Nexalin Technology's 3-Year RORE % for the quarter that ended in Mar. 2024 was -17.04%.

The industry rank for Nexalin Technology's 3-Year RORE % or its related term are showing as below:

NXL's 3-Year RORE % is ranked worse than
62.47% of 810 companies
in the Medical Devices & Instruments industry
Industry Median: -6.565 vs NXL: -17.04

Nexalin Technology 3-Year RORE % Historical Data

The historical data trend for Nexalin Technology's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology 3-Year RORE % Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
3-Year RORE %
- - - -28.64

Nexalin Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -23.65 -28.64 -17.04

Competitive Comparison of Nexalin Technology's 3-Year RORE %

For the Medical Devices subindustry, Nexalin Technology's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexalin Technology's 3-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's 3-Year RORE % falls into.



Nexalin Technology 3-Year RORE % Calculation

Nexalin Technology's 3-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.66--0.999 )/( -1.989-0 )
=0.339/-1.989
=-17.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 3-year before.


Nexalin Technology  (NAS:NXL) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Nexalin Technology 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexalin Technology (Nexalin Technology) Business Description

Traded in Other Exchanges
N/A
Address
1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Executives
Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser other: Spouse
Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology (Nexalin Technology) Headlines

From GuruFocus

Nexalin Technology CEO Provides Letter to Shareholders

By Stock market mentor Stock market mentor 01-05-2023

Nexalin Technology Provides 2022 Year-End Business Update

By sperokesalga sperokesalga 03-27-2023